Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.32 |
| ▸ | UBE2M | P61081 | 2/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068255 | 0.79 | ALDH1A1 (0.32) | ENPP1ALDH1A1KDM4EPKMLMNA | |
| SCHEMBL14108156 | 0.77 | KDM4E (0.43) | ENPP1ALDH1A1KDM4EPKMLMNA | |
| SCHEMBL3277090 | 0.77 | MAPK1 (0.39) | ENPP1ALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL4489213 | 0.74 | EGLN2 (0.31) | EGLN2ALDH1A1 | |
| SCHEMBL4473310 | 0.74 | EGLN2 (0.31) | EGLN2ALDH1A1 | |
| SCHEMBL4486324 | 0.74 | EGLN2 (0.31) | EGLN2ALDH1A1 | |
| SCHEMBL6186514 | 0.74 | SMN1; SMN2 (0.41) | ENPP1ALDH1A1KDM4ELMNACYP1A2 | |
| SCHEMBL6068253 | 0.72 | ALDH1A1 (0.32) | ALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL4265487 | 0.68 | EGLN2 (0.36) | EGLN2ENPP1ALDH1A1KDM4EPKM | |
| SCHEMBL7493866 | 0.68 | KDM4E (0.35) | EGLN2ALDH1A1KDM4EMAPK1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507739-B2 | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | EGLN2 3675/4885NOS3 4321/4885NOS1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.